factual
Three-Quarters of New Patents Are Old Drugs
More than three-quarters (78%) of drugs associated with new patents are not new drugs coming to market but existing ones, because companies begin with patent or non-patent exclusivity monopolies and repeatedly extend protection by piling on secondary patents, channeling innovation into recycling and repurposing rather than inventing genuinely new drugs.
factualpending
Speaker
Robin FeldmanEvidence Quote
“instead of innovation, we are seeing secondary patents piled onto new drugs over and over again... This is channeling innovation in a less productive direction.”
Created: 6/13/2026, 12:12:41 AM
Your notes
Loading notes...